Search results for "hepatitis c viru"

showing 10 items of 408 documents

Insulin-resistance HCV infection-related affects vascular stiffness in normotensives

2015

BACKGROUND AND AIMS. Arterial stiffness evaluated as pulse wave velocity, is an early marker of vascular damage and an independent predictor for cardiovascular events. We investigated if the insulin resistance/hyperinsulinemia chronic hepatitis C virus infection-related could influence arterial stiffness. METHODS. We enrolled 260 outpatients matched for age, body mass index, gender, ethnicity: 52 with never-treated uncomplicated chronic hepatitis C virus infection (HCV(+)), 104 never-treated hypertensives (HT) and 104 healthy subjects (NT). Pulse wave velocity was evaluated by a validated system employing high-fidelity applanation tonometry. We also measured: fasting plasma glucose and insu…

AdultMalemedicine.medical_specialtySettore MED/09 - Medicina Internamedicine.medical_treatmentArterial stiffness; Chronic hepatitis C virus infection; Insulin resistanceInsulin resistance; chronic hepatitis C virus infection; arterial stiffnessBlood PressurePulse Wave AnalysisBody Mass Indexchemistry.chemical_compoundVascular StiffnessInsulin resistanceRisk FactorsHyperinsulinismInternal medicinemedicineHyperinsulinemiaHumansInsulinPulse wave velocityCreatinineTriglyceridebusiness.industryInsulinInsulin resistanceHepatitis CHepatitis C ChronicMiddle Agedmedicine.diseaseArterial stiffnearterial stiffnessEndocrinologychemistryCase-Control StudiesHypertensionLinear ModelsArterial stiffnessFemaleCardiology and Cardiovascular MedicinebusinessChronic hepatitis C virus infection
researchProduct

Long-term course of interferon-treated chronic hepatitis C

1998

Abstract Background/Aims: To evaluate whether sustained response to α-interferon improves clinical outcome in patients with chronic hepatitis C. Methods: A cohort of 410 consecutive patients (65% with chronic hepatitis, 35% with cirrhosis) were treated with α-interferon in two trials (mean follow-up 62.1 months, range 7–109 months). All were serum HCV RNA positive before therapy and received first 10 then 5 million units of α-2b or α-n1 interferon three times weekly for 6 to 12 months. Sustained response was defined as normal aminotransferases 12 months after stopping interferon. Results: Sixty-two patients (15.1%: 54 with chronic hepatitis, eight with cirrhosis) were sustained responders. …

AdultMalemedicine.medical_specialtyTime FactorsCirrhosisHepacivirusHepatitis C virusStatistics as TopicAlpha interferonmedicine.disease_causeAntiviral AgentsGastroenterologyLiver diseaseInternal medicineAscitesmedicineHumansInterferon alfaHepatologybiologybusiness.industryInterferon-alphaHepatitis CHepatitis C ChronicMiddle Agedbiology.organism_classificationmedicine.diseaseTreatment OutcomeImmunologyFemalemedicine.symptombusinessFollow-Up Studiesmedicine.drugJournal of Hepatology
researchProduct

Epidemiology of hepatitis C virus infection in hemodialysis patients of Sicily

2008

AdultMalemedicine.medical_specialtymedicine.medical_treatmentHepatitis C virusBiomedical EngineeringMedicine (miscellaneous)BioengineeringHepacivirusmedicine.disease_causeBiomaterialsYoung AdultRenal DialysisEpidemiologymedicinePrevalenceHumansSicilyAgedAged 80 and overbusiness.industryGeneral MedicineHepatitis C AntibodiesHepatitis C ChronicMiddle AgedViral LoadVirologyChronic DiseaseRNA ViralFemaleKidney DiseasesHemodialysisbusiness
researchProduct

Hepatitis C virus viral kinetics during α-2a or α-2b pegylated interferon plus ribavirin therapy in liver transplant recipients with different immuno…

2012

Abstract Background Predictors of sustained virological response (SVR) to antiviral therapy post-liver transplantation (LT) for chronic hepatitis C are needed. In non-transplanted patients, viral kinetics can predict SVR. Objectives To determine the early viral kinetics in LT recipients with different immunosuppression (tacrolimus – Tac- vs. cyclosporine – CsA-) during treatment with peg-IFN + RBV. Study design Prospective pilot study in HCV-1b infected patients: (LT CsA n = 8; Tac n = 8; non-LT n = 4), treated with IFN α-2a vs. α-2b (180 μg or 1.5 μg/kg, respectively) once weekly plus weight-based RBV. Median CsA or Tac baseline trough levels were 141 and 7.70 ng/mL, respectively. HCV-RNA …

AdultMalemedicine.medical_specialtymedicine.medical_treatmentHepatitis C virusPilot ProjectsHepacivirusInterferon alpha-2Biologymedicine.disease_causeAntiviral AgentsGastroenterologyPolyethylene GlycolsImmunocompromised Hostchemistry.chemical_compoundPegylated interferonVirologyInternal medicineRibavirinmedicineHumansProspective StudiesAgedRibavirinInterferon-alphaImmunosuppressionHepatitis C ChronicMiddle AgedViral LoadViral kineticsRecombinant ProteinsTacrolimusLiver TransplantationTransplantationKineticsTreatment OutcomeInfectious DiseaseschemistryHost-Pathogen InteractionsImmunologyFemaleViral loadmedicine.drugJournal of Clinical Virology
researchProduct

Infection with human herpes virus type 8 in an area at high prevalence for hepatitis C virus infection in southern Italy

2004

Summary.  The Campania Region is a geographical area of southern Italy characterized by high incidence rates of hepatocellular carcinoma and of classic Kaposi's sarcoma. Epidemiological investigations carried out among different population groups in this region have found high prevalence rates of both hepatitis C virus (HCV) and human herpesvirus type 8 (HHV-8). To assess co-infection rates of HCV and HHV-8, we carried out a cross-sectional seroepidemiological study prevalence in Pomigliano d'Arco, a Health District of Campania located 20 km away from Naples. The overall rate of HCV/HHV-8 co-infection was 3.1%, 3.5% among men and 2.7% among women. No difference emerged in the HCV/HHV-8 co-i…

AdultMalemedicine.medical_specialtyvirusesHepatitis C virusPopulationAntibodies Viralmedicine.disease_causeSeroepidemiologic StudiesVirologyEpidemiologyHumansMedicineeducationAgededucation.field_of_studyHigh prevalenceHepatologybusiness.industryTransmission (medicine)Human herpes virusPublic healthvirus diseasesHerpesviridae InfectionsHepatitis C AntibodiesMiddle Agedmedicine.diseaseHepatitis CVirologyCross-Sectional StudiesInfectious DiseasesItalyHepatocellular carcinomaHerpesvirus 8 HumanFemalebusinessJournal of Viral Hepatitis
researchProduct

Retrospective, observational, multicentre study on an Italian population affected by chronic hepatitis C who failed to clear HCV-RNA after the combin…

2010

There is a lack of information on the characteristics of patients with chronic hepatitis C virus infection (HCV) who fail to respond to antiviral treatment. We studied HCV-positive subjects with chronic liver diseases treated with pegylated-interferon (PEG-IFN) and ribavirin (RBV) who failed to clear HCV in routine clinical practice. A total of 2150 consecutive adult patients treated with PEG-IFN plus RBV therapy in 46 Italian centres between 1 July 2004, and 30 June 2005, were studied. Of the 2150 patients, 923 (42.9%) (M/F 585/335, mean age 54.8 years) failed to achieve a serum HCV-RNA clearance. Of these 923 patients, 429 (46.5%) were nonresponders, 298 (32.3%) relapsers, 168 (18.2%) dro…

AdultMalenon-responders.relapserGenotypebody mass index; cirrhosis; hepatitis c virus; nonresponder; pegylated-interferon; relapserInfectious Diseasebody mass indexHepacivirusvirusInterferon alpha-2Antiviral AgentsPolyethylene GlycolPolyethylene GlycolsMedication Adherencebody mass index; cirrhosis; hepatitis C; virus; nonresponder; pegylated-interferon; relapserRisk FactorsRetrospective StudienonresponderVirologyRibavirinHumansAge FactorTreatment FailureRetrospective StudiesAgedAntiviral AgentSettore MED/12 - GastroenterologiaHCV; Antiviral therapy; Body mass index; Cirrhosis; Hepatitis C virus; Nonresponder; Pegylated-interferon; RelapserCirrhosiHepaciviruHepatologyRisk FactorcirrhosisAge FactorsInterferon-alphahepatitis c virusHepatitis C ChronicMiddle AgedRecombinant ProteinRecombinant ProteinsItalyRNA ViralFemalehepatitis Cpegylated-interferonHepatitis C viruHuman
researchProduct

Genetic variability of hepatitis C virus non-structural protein 3 and virus-specific CD8+ response in patients with chronic hepatitis C.

2004

Hepatitis C virus (HCV) variation in specific T-cell epitopes may represent a mechanism of viral persistence in chronic infection. We examined the HCV non-structural protein 3 (NS3), including the immunologically relevant epitopes HCV NS3-2 KLVALGINAV (human leukocyte antigen [HLA]-A2-restricted) and HCV NS3-1391 LIFCHSKKK (HLA-A3-restricted), in 22 HLA-A2+ patients with chronic infection. Significant amino acid variation was found in HCV NS3-2 epitope sequences when compared to the HCV-1 prototype virus. Six of the nine different HCV NS3-2 peptide variants were identified in patients with HCV NS3-2-specific CD8+ cells, detected with an HLA-A2 tetramer made with the HCV-1 prototype peptide.…

AdultMalevirusesHepacivirusHepatitis C virusMolecular Sequence DataEpitopes T-LymphocyteHuman leukocyte antigenHepacivirusCD8-Positive T-LymphocytesHLA-A3 AntigenViral Nonstructural Proteinsmedicine.disease_causeEpitopeVirusFlaviviridaeVirologySequence Homology Nucleic AcidHLA-A2 AntigenmedicineHumansAmino Acid SequencePhylogenyAgedNS3Polymorphism GeneticbiologyGenetic heterogeneityReverse Transcriptase Polymerase Chain Reactionvirus diseasesGenetic VariationHepatitis C ChronicMiddle Agedbiology.organism_classificationVirologydigestive system diseasesInfectious DiseasesImmunologyRNA ViralFemaleHepatitis C AntigensJournal of medical virology
researchProduct

Transglutaminase Type II Plays a Protective Role in Hepatic Injury

2003

The up-regulation of "tissue" transglutaminase (TG2) gene has been shown to occur in various pathologies and can lead to severe liver injury; however, its role in the onset of liver damage has not yet been clarified. To address this issue, we have used two experimental settings: carbon tetrachloride (CCl(4))-induced liver injury in wild-type and TG2 knockout mice; and liver biopsies obtained from a large cohort of hepatitis C virus (HCV)-infected patients. Mice lacking TG2 failed to clear the hepatic necrotic tissue formed in response to prolonged CCl(4) exposure (5 weeks) and 60% of them died before the end of the treatment. By contrast, wild-type mice were able to recover after the toxic …

AdultPathologymedicine.medical_specialtyNecrosisGenotypeTissue transglutaminaseHepatitis C virusCCL4medicine.disease_causeGene Expression Regulation EnzymologicPathology and Forensic MedicineExtracellular matrixMiceNecrosisGTP-Binding ProteinsmedicineAnimalsHumansProtein Glutamine gamma Glutamyltransferase 2Mice KnockoutHepatitisLiver injuryTransglutaminasesbiologyCarbon Tetrachloride PoisoningHepatitis C ChronicMiddle Agedmedicine.diseaseMice Inbred C57BLLiverKnockout mousebiology.proteinmedicine.symptomRegular ArticlesThe American Journal of Pathology
researchProduct

Serum malondialdehyde: possible use for the clinical management of chronic hepatitis C patients

1998

Serum lipid peroxidation products are increased in inflammatory liver disease and, as we previously reported, also in chronic hepatitis C. We have performed a specific assay of malondialdehyde, the reported most abundant product of lipid peroxidation, in serum of twenty four chronic hepatitis C patients, before, during, and after interferon treatment. Liver biopsies were performed in each patient before and after interferon treatment. The results show higher serum malondialdehyde values in chronic hepatitis C patients than healthy subjects (n = 68) before interferon treatment (p < .001). Mean value of serum malondialdehyde levels after interferon treatment was significantly lower than befor…

Adultmedicine.medical_specialtyHepatitis C virusmedicine.disease_causeBiochemistryGastroenterologyLipid peroxidationchemistry.chemical_compoundLiver diseaseChronic hepatitisInterferonMalondialdehydePhysiology (medical)Internal medicineBiopsymedicineHumansmedicine.diagnostic_testbusiness.industryInterferon-alphaAlanine TransaminaseHepatitis C ChronicMiddle AgedMalondialdehydemedicine.diseasechemistryImmunologybusinessOxidative stressmedicine.drugFree Radical Biology and Medicine
researchProduct

Duration of HCV infection as a predictor of nonresponse to interferon

1996

Duration of hepatitis C virus (HCV) infection is a key feature in determining responsiveness to interferon (IFN). Studies assessing its value as a predictive factor in chronic HCV infection show that a long duration of infection reduces the likelihood of a sustained response to IFN (defined as ALT normalization and clearance of serum HCV-RNA). The effect of HCV infection duration is independent of the presence of cirrhosis and level of HCV viremia. Meta-analysis of IFN trials in acute HCV infection shows an obvious effect of the drug on long-term ALT normalization and HCV-RNA clearance. Treatment of HCV infection during the acute or early chronic phase could therefore maximize therapeutic e…

Adultmedicine.medical_specialtyTime FactorsCirrhosisPhysiologyHepatitis C virusAlpha interferonViremiaHepacivirusmedicine.disease_causeInternal medicinemedicineHumansTreatment FailureInterferon alfabusiness.industryGastroenterologyInterferon-alphavirus diseasesHepatitis CHepatologymedicine.diseaseHepatitis Cdigestive system diseasesAcute DiseaseChronic DiseaseImmunologyRNA ViralViral diseasebusinessmedicine.drug
researchProduct